Probiotic Use for Recovery Enhancement From Long COVID-19
NCT ID: NCT06643299
Last Updated: 2025-09-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
180 participants
INTERVENTIONAL
2025-05-13
2026-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Investigation of the Use of a Probiotic Supplement in People With Long COVID
NCT05975034
WHO COVID-19 - Evaluation of the Efficacy of Probiotics to Reduce the Occurrence of Long COVID
NCT05080244
Immune and Recovery Modulating Impact of Probiotic Supplementation After Intense Resistance Exercise
NCT04441840
Effect of Probiotic Strain Lactobacillus Paracasei PS23 on Brain Fog in People With Long COVID
NCT06348212
Changes in Viral Load in COVID-19 After Probiotics
NCT04666116
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Do probiotics reduce the number and severity of symptoms in those with Long COVID?
2. Do probiotics improve the physical and mental health quality of life in those with Long COVID?
3. Do probiotics improve return to work and daily activities in those with Long COVID?
Researchers will compare probiotics to a placebo (a look-alike substance that contains no probiotics) to see if probiotics work to treat Long COVID.
Participants will take the study medication (placebo or probiotic) for 4 months. They will then cross over (take the other medication) for an additional 4 months. Participants will complete a survey at baseline, 4 months, and 8 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Probiotic Arm
Probiotic pill taken once daily
Probiotic Agent
BlueBiology: Ultimate Care probiotic pill taken once daily for a four-month period.
Placebo Arm
Identical placebo pill taken once daily
Placebo
Placebo produced to be identical in taste and appearance to the probiotic agent, taken once daily for a four-month period.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Probiotic Agent
BlueBiology: Ultimate Care probiotic pill taken once daily for a four-month period.
Placebo
Placebo produced to be identical in taste and appearance to the probiotic agent, taken once daily for a four-month period.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Are unable to take the study medication daily
* Are currently pregnant or planning to become pregnant over the course of the study
* Are currently breastfeeding
* Have been diagnosed with an immune-compromising condition
* Are currently taking immunosuppressants
* Do not speak English as a primary language
* Are regularly taking probiotics
* Are enrolled in another Long COVID study with an intervention
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rush University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Michael Gottlieb
Professor of Emergency Medicine, Vice Chair of Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rush University Medical Center
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
24082903
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.